Impact of the COVID-19 Pandemic on Psychosis
The implications of the COVID-19 pandemic will have pervasive effects on schizophrenia and psychosis research and clinical services worldwide. In this webinar, four presenters share research on the impact of the COVID-19 pandemic on psychosis.
Presented By
Gemma Modinos Institute of Psychiatry, Psychology & Neuroscience, King's College London | United Kingdom Chair and Moderator
James MacCabe Institute of Psychiatry, Psychology and Neuroscience, King’s College London | United Kingdom Clozapine Treatment and Risk of COVID-19 Emily A. Troyer University of California San Diego Department of Psychiatry Hong Laboratory | United States Potential Impact of COVID-19 on Psychosis Risk and Symptomatology
SIRS 2019 Meeting Presentations
SIRS 2019 Meeting Presentations
Kristen Brennand: Modeling The Impact Of Rare And Common Variants In Schizophrenia Using Stem Cells
Deanna Kelly: Schizophrenia And Gluten New Target And Precision Medicine
Steven Leifman: Awards And Keynote Speaker Judge Steven Leifman
Anthony Morrison: Cognitive Behavior Therapy For People With Psychosis
Sohee Park: Schizophrenia In The Flesh, The Case For Behavioral Sciences In The Age Of Big Data
Jessica Turner: International Collaborative Efforts In The Enigma Schizophrenia Working Group
SIRS 2018 Meeting Presentations
SIRS 2018 Meeting Presentations
William Carpenter: The Near Future for Schizophrenia (Psychosis) Research
Guusje Collin: Abnormal Modular Organization of the Functional Connectome Predicts Conversion to Psychosis in Clinical High-Risk Youth
Vanessa Cropley: Increased Complement Factors C3 and C4 in Schizophrenia and the Early Stages of Psychosis: Implications for Clinical Symptomatology and Cortical Thickness
John Cryan: The Gut Microbiome: A Key Regulator of Neurodevelopment and Behaviour
Melanie Föcking: Proteomic Analysis of Blood-Based Samples From the Optimise (OPtimization of Treatment and Management of Schizophrenia in Europe) Study Point Towards Complement Pathway Protein Changes
John Gilmore: Early Brain and Cognitive Development in Children at Risk for Schizophrenia
Anthony Grace: Stress-Induced Amygdala Hyperactivity Leads to Interneuron Loss and Schizophrenia-Like Pathology in a Developmental Disruption Model of Schizophrenia
Margaret Hahn: Olanzapine Impairs Central Insulin Action: Effects on Body Fuel Preference in Rats
Viktoria Johansson: Cerebrospinal Fluid Findings in Twins with Psychotic Symptoms – Novel Findings and Future Prospects
Kenneth Koblan: SEP-363856, a Candidate Antipsychotic and Antidepressant Compound With a Novel Non-D2 Mechanism of Action
Martin K. Rimvall: Psychotic Experiences are Associated With Health Anxiety and Functional Somatic Symptoms in Pre-Adolescence
André Schmidt: Disorganized Gyrification Network Properties During the Transition to Psychosis
Sara Tomiello: A Computational Trial-By-Trial EEG Analysis of Hierarchical Precision-Weighted Prediction Errors
Daniel Umbricht: Using Imaging and Behavioral Methods Probing Reward Functions as Tools for Decision Making in a Proof-Of-Mechanism Study of the PDE10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms
Thomas Weickert: ICAM-1 is Increased in Brain and Peripheral Levels of Soluble ICAM-1 is Related to Cognitive Deficits in Schizophrenia
Dom's Story
Imagine being a child inflicted with hallucinations and delusions so frightening that you cannot differentiate between our world and a living nightmare. Welcome to Dom's world. Dom was diagnosed with Childhood Schizophrenia at age 10. This is Dom's Story.
